Skip to content

Study · Randomized controlled trial · n = 30 · 2018

11 results

Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.

Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J

Diabetes, obesity & metabolism27 Oct 2017Cited by 195 (Europe PMC)

PMID28941314 (opens in a new tab)PMCIDPMC5836914 (opens in a new tab)DOI10.1111/dom.13120 (opens in a new tab)PepBankPUB-28941314
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, semaglutide lowered fasting glucose versus placebo.

    In plain wordsIn adults with obesity, semaglutide lowered fasting blood glucose compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting glucose
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Estimated treatment ratio
    0.95 ratio
    fasting glucose

    Source sentences

    Summary
    Semaglutide treatment significantly lowered fasting concentrations of glucose and glucagon, and increased insulin vs placebo (estimated treatment ratio: 0.95 [95% confidence interval: 0.91, 0.98]; 0.86 [0.75, 0.98]; 1.45 [1.20, 1.75], respectively).
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, semaglutide lowered fasting glucagon versus placebo.

    In plain wordsIn adults with obesity, semaglutide lowered fasting glucagon compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting glucagon
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Estimated treatment ratio
    0.86 ratio
    fasting glucagon

    Source sentences

    Summary
    Semaglutide treatment significantly lowered fasting concentrations of glucose and glucagon, and increased insulin vs placebo (estimated treatment ratio: 0.95 [95% confidence interval: 0.91, 0.98]; 0.86 [0.75, 0.98]; 1.45 [1.20, 1.75], respectively).
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, semaglutide increased fasting insulin versus placebo.

    In plain wordsIn adults with obesity, semaglutide raised fasting insulin compared with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseFasting insulin
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Estimated treatment ratio
    1.45 ratio
    fasting insulin

    Source sentences

    Summary
    Semaglutide treatment significantly lowered fasting concentrations of glucose and glucagon, and increased insulin vs placebo (estimated treatment ratio: 0.95 [95% confidence interval: 0.91, 0.98]; 0.86 [0.75, 0.98]; 1.45 [1.20, 1.75], respectively).
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, semaglutide improved postprandial glucose iAUC versus placebo.

    In plain wordsIn adults with obesity, semaglutide lowered the rise in blood glucose after meals compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePostprandial glucose (iAUC 0-5h)
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    iAUC0-5h difference
    −1.34 mmol h/L
    glucose

    Source sentences

    Summary
    Postprandial glucose metabolism significantly improved with semaglutide vs placebo (incremental area under the curve 0 to 5 hours [iAUC0-5h ]; estimated treatment difference: glucose -1.34 mmol h/L [-2.42, -0.27]; insulin -921 pmol h/L [-1461, -381]; C-peptide -1.42 nmol h/L [-2.33, -0.51]).
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, semaglutide lowered postprandial insulin iAUC versus placebo.

    In plain wordsIn adults with obesity, semaglutide lowered the insulin rise after meals compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePostprandial insulin (iAUC 0-5h)
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    iAUC0-5h difference
    −921 pmol h/L
    insulin

    Source sentences

    Summary
    Postprandial glucose metabolism significantly improved with semaglutide vs placebo (incremental area under the curve 0 to 5 hours [iAUC0-5h ]; estimated treatment difference: glucose -1.34 mmol h/L [-2.42, -0.27]; insulin -921 pmol h/L [-1461, -381]; C-peptide -1.42 nmol h/L [-2.33, -0.51]).
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, semaglutide lowered postprandial C-peptide iAUC versus placebo.

    In plain wordsIn adults with obesity, semaglutide lowered the C-peptide rise after meals compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePostprandial C-peptide (iAUC 0-5h)
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    iAUC0-5h difference
    −1.42 nmol h/L
    C-peptide

    Source sentences

    Summary
    Postprandial glucose metabolism significantly improved with semaglutide vs placebo (incremental area under the curve 0 to 5 hours [iAUC0-5h ]; estimated treatment difference: glucose -1.34 mmol h/L [-2.42, -0.27]; insulin -921 pmol h/L [-1461, -381]; C-peptide -1.42 nmol h/L [-2.33, -0.51]).
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, fasting and postprandial lipid metabolism improved with semaglutide versus placebo.

    In plain wordsIn adults with obesity, semaglutide improved blood fat measures, fasting and after meals, compared with placebo.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedFasting and postprandial lipid metabolism
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Fasting and postprandial lipid metabolism improved with semaglutide vs placebo.
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.
  8. 08HumanRandomized controlled trialMechanism

    In adults with obesity, semaglutide delayed first-hour gastric emptying after the meal versus placebo.

    In plain wordsIn adults with obesity, semaglutide slowed stomach emptying in the first hour after a meal compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseFirst-hour gastric emptying (AUC 0-1h)
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Estimated treatment ratio
    0.73 ratio
    AUC0-1h

    Source sentences

    Summary
    First-hour gastric emptying after the meal was delayed with semaglutide vs placebo (AUC0-1h ; estimated treatment ratio: 0.73 [0.61, 0.87]); this may have contributed to the lower postprandial glucose increase in semaglutide-treated subjects.
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.
  9. 09HumanRandomized controlled trialMechanism

    In adults with obesity, overall gastric emptying did not differ significantly between semaglutide and placebo.

    In plain wordsIn adults with obesity, overall stomach emptying over five hours did not differ between semaglutide and placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeOverall gastric emptying (AUC 0-5h)
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Overall gastric emptying (AUC0-5h ) was not statistically different between treatments.
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.
  10. 10HumanRandomized controlled trialMechanism

    In adults with obesity, the fasting peptide YY response was lower with semaglutide than with placebo.

    In plain wordsIn adults with obesity, the fasting peptide YY response was lower with semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting PYY response
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Endocrine and hormones
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Fasting and postprandial PYY responses were significantly lower with semaglutide vs placebo (P = .0397 and P = .0097, respectively).
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.
  11. 11HumanRandomized controlled trialMechanism

    In adults with obesity, the postprandial peptide YY response was lower with semaglutide than with placebo.

    In plain wordsIn adults with obesity, the peptide YY response after meals was lower with semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePostprandial PYY response
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Endocrine and hormones
    Studied dose
    dose-escalated to 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Fasting and postprandial PYY responses were significantly lower with semaglutide vs placebo (P = .0397 and P = .0097, respectively).
    2 context sentences
    Summary · context
    This was a randomized, double-blind, placebo-controlled, 2-period, crossover trial.
    Summary · context
    Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 not yet recruiting · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT07617155

GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis

Peking Union Medical College Hospitaln = 396est. Sept 2026 to est. Dec 2028

Hypertriglyceridemia Induced Acute Pancreatitis · Recurrent Acute Pancreatitis · Pancreatitis Relapsing · Hypertriglyceridemia

Trial pageClinicalTrials.govUpdated 1 Jun 2026
CompletedPhase 1NCT02079870

Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Novo Nordisk A/Sn = 306 Mar 2014 to 7 Jan 2015

Diabetes · Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 2 Dec 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.